Heidi Schwarzenbach
Priv.-Doz. Dr. phil. nat.
Heidi Schwarzenbach
  • Scientist
Working area


Campus Forschung N27 , 4th Floor, Room number 04.005
German (Mother tongue)


  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2004
  • 2003
  • 2002
  • 1996
  • 1995
  • 1994
  • 1990

Recent advances in Circulating Nucleic Acids in oncology
Otandault A, Anker P, Al Amir Dache Z, Guillaumon V, Meddeb R, Pastor B, Pisareva E, Sanchez C, Tanos R, Tousch G, Schwarzenbach H, Thierry A
ANN ONCOL. 2019;30(3):374-384.

The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder
Rink M, Schwarzenbach H, Riethdorf S, Soave A
WORLD J UROL. 2019;37(9):1785-1799.

The current role of circulating biomarkers in non-muscle invasive bladder cancer
Rink M, Schwarzenbach H, Vetterlein M, Riethdorf S, Soave A
Transl Androl Urol. 2019;8(1):61-75.

Copy Number Variation Analysis on Cell-Free Serum DNA
Schwarzenbach H
2019. Cell-free DNA as Diagnostic Markers. Casadio V, Salvi S (eds.). 1. ed. New York: Humana Press, 85-93.

Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment DiMoPEx-project is designed to determine the impacts of environmental exposure on human health
Budnik L, Adam B, Albin M, Banelli B, Baur X, Belpoggi F, Bolognesi C, Broberg K, Gustavsson P, Göen T, Fischer A, Jarosinska D, Manservisi F, O'Kennedy R, Øvrevik J, Paunovic E, Ritz B, Scheepers P, Schlünssen V, Schwarzenbach H, Schwarze P, Sheils O, Sigsgaard T, Van Damme K, Casteleyn L

Clinical relevance of size selection of circulating DNA
Grunt M, Hildebrand T, Schwarzenbach H
TRANSL CANCER RES. 2018;7(Suppl 2):S171-S184.

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
Ni Q, Stevic I, Pan C, Müller V, Oliviera-Ferrer L, Pantel K, Schwarzenbach H
SCI REP-UK. 2018;8:12974.

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
Pan C, Stevic I, Müller V, Ni Q, Ferrer L, Pantel K, Schwarzenbach H
MOL ONCOL. 2018;12(11):1935-1948.

An inside view on liquid biopsies
Schwarzenbach H
TRANSL CANCER RES. 2018;7(Suppl 2):S99-S100.

Methods for quantification and characterization of microRNAs in cell-free plasma/serum, normal exosomes and tumor-derived exosomes
Schwarzenbach H
TRANSL CANCER RES. 2018;7(Suppl 2):S253-S263.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
Stevic I, Müller V, Weber K, Fasching P, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H
BMC MED. 2018;16(1):179.

Plasma microRNA signature is associated with risk stratification in prostate cancer patients
Al-Qatati A, Akrong C, Stevic I, Pantel K, Awe J, Saranchuk J, Drachenberg D, Mai S, Schwarzenbach H
INT J CANCER. 2017;141(6):1231-1239.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B
ONCOTARGET. 2017;8(29):48507-48520.

Clinical Relevance of Circulating, Cell-Free and Exosomal microRNAs in Plasma and Serum of Breast Cancer Patients
Schwarzenbach H
ONCOL RES TREAT. 2017;40(7-8):423-429.

Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study
Soave A, Chun F, Hillebrand T, Rink M, Weisbach L, Steinbach B, Fisch M, Pantel K, Schwarzenbach H
ONCOTARGET. 2017;8(34):56398-56407.

Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer
Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H
ADV EXP MED BIOL. 2016;924:3-8.

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H
ONCOTARGET. 2016;7(13):16923-35.

Novel Technology for Enrichment of Biomolecules from Cell-Free Body Fluids and Subsequent DNA Sizing
Patel V, Celec P, Grunt M, Schwarzenbach H, Jenneckens I, Hillebrand T
ADV EXP MED BIOL. 2016;924:165-169.

Biological and Clinical Relevance of H19 in Colorectal Cancer Patients
Schwarzenbach H
EBioMedicine. 2016;13:9-10.

Clinical significance of miR-15 and miR-16 in ovarian cancer.
Schwarzenbach H
TRANSL CANCER RES. 2016;5:50-53.

Diagnostic relevance of circulating cell-free and exosomal microRNAs and long non-coding RNAs in blood of cancer patients.
Schwarzenbach H
LABORATORIUMSMEDIZIN. 2016;40(5):345-353.

Biomonitoring nach Dichlormethan/1,2-Dichlorethan-Exposition: Eine Pilotstudie.
Budnik L, Schwarzenbach H, Kloth S, Eckert E, Göen T
2015. Dokumentation der 55. Jahrestagung der DGAUM 2015. Hildenbrand S, Rieger M (eds.). 115-7.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
Meng X, Joosse S, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H
BRIT J CANCER. 2015;113(9):1358-1366.

CNAPS and General Medicine
Schwarzenbach H
2015. Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring. Gahan P (eds.). 1. ed. Springer, 143-164.

The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer
Schwarzenbach H
EXPERT REV MOL DIAGN. 2015;15(9):1159-69.

The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response
Schwarzenbach H
EXPERT REV MOL DIAGN. 2015;15(2):267-75.

Data Normalization Strategies for MicroRNA Quantification
Schwarzenbach H, Machado da Silva A, Calin G, Pantel K
CLIN CHEM. 2015;61(11):1333-42.

Circulating DNA as biomarker in breast cancer
Schwarzenbach H, Pantel K
BREAST CANCER RES. 2015;17:Art. 136.

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients
Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H
ONCOTARGET. 2015;6(15):13387-401.

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman-Kocher H, Pantel K, Schwarzenbach H
ONCOTARGET. 2014;5(20):9650-63.

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
Joosse S, Müller V, Steinbach B, Pantel K, Schwarzenbach H
BRIT J CANCER. 2014;111(5):909-17.

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial
Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching P, Mau C, Pantel K, Schwarzenbach H
BREAST CANCER RES TR. 2014;147(1):61-8.

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein
Schwarzenbach H, Eichelser C, Steinbach B, Tadewaldt J, Pantel K, Lobanenkov V, Loukinov D
BMC CANCER. 2014;14:796.

Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach H, Nishida N, Calin G, Pantel K
NAT REV CLIN ONCOL. 2014;11(3):145-156.

Circulating MicroRNAs as Non-Invasive Biomarkers
Schwarzenbach H, Pantel K
2014. MicroRNAs in Medicine. Lawrie C (eds.). 1. ed. Wiley-Blackwell, 567-588.

Circulating mitochondrial DNA as biomarker linking environmental chemical exposure to early preclinical lesions elevation of mtDNA in human serum after exposure to carcinogenic halo-alkane-based pesticides
Budnik L, Kloth S, Baur X, Preisser A, Schwarzenbach H
PLOS ONE. 2013;8(5):e64413.

Expression Regulation of the Metastasis-Promoting Protein InsP3-Kinase-A in Tumor Cells.
Chang L, Schwarzenbach H, Meyer-Staeckling S, Brandt B, Mayr G, Weitzel J, Windhorst S

Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression
Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H
CLIN CHEM. 2013;59(10):1489-96.

Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis
Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y
CANCER CELL. 2013;24(4):542-56.

Circulating nucleic acids as biomarkers in breast cancer
Schwarzenbach H
BREAST CANCER RES. 2013;15(5):211.

Loss of Heterozygosity
Schwarzenbach H
2013. Brenner´s Encyclopedia of Genetics. Maloy S, Hughes K (eds.). 2.. ed. Brenner, 271-273.

Circulating tumor cells and circulating tumor DNA.
Alix-Panabières C, Schwarzenbach H, Pantel K
ANNU REV MED. 2012;63:199-215.

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.
Kuhlmann J, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R, Kasimir-Bauer S
BMC CANCER. 2012;12:325.

Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
Roth C, Stückrath I, Pantel K, Izbicki J, Tachezy M, Schwarzenbach H
PLOS ONE. 2012;7(6):38248.

Circulating nucleic acids and protease activities in blood of tumor patients.
Schwarzenbach H
EXPERT OPIN BIOL TH. 2012;12 Suppl 1:163-169.

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.
Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K
CLIN CANCER RES. 2012;18(20):5719-5730.

Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.
Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K
BREAST CANCER RES TR. 2012;134(3):933-941.

Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.
Kuhlmann J, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm K, Kimmig R, Kasimir-Bauer S
GENE CHROMOSOME CANC. 2011;50(8):598-605.

Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence.
Rawnaq T, Schwarzenbach H, Schurr P, Freise K, Brandl S, Izbicki J, Kaifi J
J SURG RES. 2011;169(1):31-35.

Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.
Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H
MOL ONCOL. 2011;5(3):281-291.

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression.
Roth C, Pantel K, Müller V, Rack B, Kasimir-Bauer S, Janni W, Schwarzenbach H
BMC CANCER. 2011;11:4.

Circulating microRNAs: promising breast cancer biomarkers - author´s response
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H
BREAST CANCER RES. 2011;13(1):403.

Impact of physical activity and doping on epigenetic gene regulation.
Schwarzenbach H
DRUG TEST ANAL. 2011;3(10):682-687.

Prostate Cancer - From Bench to Bedside
Schwarzenbach H
2011. Prostate Cancer - From Bench to Bedside. 1. ed. InTec, 115-132.

Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients.
Schwarzenbach H, Chun F, Isbarn H, Huland H, Pantel K
J CANCER RES CLIN. 2011;137(5):811-819.

Cell-free nucleic acids as biomarkers in cancer patients.
Schwarzenbach H, Hoon D, Pantel K
NAT REV CANCER. 2011;11(6):426-437.

Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease.
Schwarzenbach H, Müller V, Milde-Langosch K, Steinbach B, Pantel K
Mol Biosyst. 2011;7(10):2848-2854.

Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H
INT J CANCER. 2011;128(11):2572-2580.

Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
Müller I, Wischnewski F, Pantel K, Schwarzenbach H
BMC CANCER. 2010;10:297.

Increase in circulating microRNA levels in blood of ovarian cancer patients
Roth C, Kasimir-Bauer S, Heubner M, Pantel K, Schwarzenbach H
2010. Circulating nucleic acids in plasma and serum. Gahan P (eds.). 1.. ed. Springer, 63-71.

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H
BREAST CANCER RES. 2010;12(6):90.

Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy
Schwarzenbach H
EPMA J. 2010;1(3):485-494.

Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma.
Schwarzenbach H, Goekkurt E, Pantel K, Aust D, Stoehlmacher J
INT J CANCER. 2010;127(4):881-888.

PSA and Prostate
Schwarzenbach H, Pantel K
2010. PSA and Prostate. Nova Science Publishers, 65-85.

Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.
Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell J, Rebillard X, Pantel K
CLIN CANCER RES. 2009;15(3):1032-1038.

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, Kasimir-Bauer S
BREAST CANCER RES. 2009;11(5):71.

Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.
Müller I, Beeger C, Alix-Panabières C, Rebillard X, Pantel K, Schwarzenbach H
CLIN CHEM. 2008;54(4):688-696.

Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H, Chun F, Müller I, Seidel C, Urban K, Erbersdobler A, Huland H, Pantel K, Friedrich M
BJU INT. 2008;102(2):253-258.

Methods of cancer diagnosis, therapy and prognosis
Schwarzenbach H, Pantel K
2008. Methods of cancer diagnosis, therapy and prognosis. Springer, 481-497.

Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer.
Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E
ANN NY ACAD SCI. 2008;1137:190-196.

Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
Schwarzenbach H, Chun F, Lange I, Carpenter S, Gottberg M, Erbersdobler A, Friedrich M, Huland H, Pantel K
INT J CANCER. 2007;120(7):1465-1471.

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
Schwarzenbach H, Müller V, Beeger C, Gottberg M, Stahmann N, Pantel K
BREAST CANCER RES. 2007;9(5):66.

Similar patterns of loss of heterozygosity in serum of adenocarcinoma of the distal oesophagus and the cardia in early diagnosis.
Wachowiak R, Kaifi J, Schurr P, Merkert P, Yekebas E, Schwarzenbach H, Strate T, Sauter G, Izbicki J
ANTICANCER RES. 2007;27(1):477-481.

Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.
Wachowiak R, Kaifi J, Schwarzenbach H, Yekebas E, Merkert P, Schurr P, Hansen B, Reichelt U, Strate T, Pantel K, Izbicki J
DIAGN MOL PATHOL. 2007;16(3):174-178.

Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
Wischnewski F, Friese O, Pantel K, Schwarzenbach H
MOL CANCER RES. 2007;5(7):749-759.

Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer
Schwarzenbach H, Müller V, Stahmann N, Pantel K
ANN NY ACAD SCI. 2004;1022:25-32.

Gonadotropin-mediated regulation of the murine VEGF expression in MA-10 Leydig cells
Schwarzenbach H, Chakrabarti G, Paust H, Mukhopadhyay A
J ANDROL. 2003;25(1):128-39.

Stimulatory effect of progesterone on the expression of steroidogenic acute regulatory protein in MA-10 Leydig cells
Schwarzenbach H, Manna P, Stocco D, Chakrabarti G, Mukhopadhyay A
BIOL REPROD. 2003;68(3):1054-63.

A diagnostic tool for monitoring multidrug resistance expression in human tumor tissues
Schwarzenbach H
ANAL BIOCHEM. 2002;308(1):26-33.

Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma
Schwarzenbach H
MED ONCOL. 2002;19(2):87-104.

Gene structure and characterization of the murine homologue of the B cell-specific transcriptional coactivator OBF-1
Schubart D, Sauter P, Massa S, Friedl E, Schwarzenbach H, Matthias P
NUCLEIC ACIDS RES. 1996;24(10):1913-20.

Involvement of the Ets family factor PU.1 in the activation of immunoglobulin promoters
Schwarzenbach H, Newell J, Matthias P
J BIOL CHEM. 1995;270(2):898-907.

Octamer factors exert a dual effect on the IL-2 and IL-4 promoters
Pfeuffer I, Klein-Hessling S, Heinfling A, Chuvpilo S, Escher C, Brabletz T, Hentsch B, Schwarzenbach H, Matthias P, Serfling E
J IMMUNOL. 1994;153(12):5572-85.

Interleukin 1 and tumor necrosis factor stimulate cGMP formation in rat renal mesangial cells
Pfeilschifter J, Schwarzenbach H
FEBS LETT. 1990;273(1-2):185-7.

Letzte Aktualisierung aus dem FIS: 09.08.2020 - 06:37 Uhr